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Abstract
Background: In an increasingly comorbid population, there are significant challenges to diagnosing the cause of breathlessness,
and once diagnosed, considerable difficulty in detecting deterioration early enough to provide effective intervention. The burden
of the breathless patient on the health care economy is substantial, with asthma, chronic heart failure, and pneumonia affecting
over 6 million people in the United Kingdom alone. Furthermore, these patients often have more than one contributory factor to
their breathlessness symptoms, with conditions such as dysfunctional breathing pattern disorders—an under-recognized component.
Current methods of diagnosing and monitoring breathless conditions can be extensive and difficult to perform. As a consequence,
home monitoring is poorly complied with. In contrast, capnography (the measurement of tidal breath carbon dioxide) is performed
during normal breathing. There is a need for a simple, easy-to-use, personal device that can aid in the diagnosis and monitoring
of respiratory and cardiac causes of breathlessness.
Objective: The aim of this study was to explore the use of a new, handheld capnometer (called the N-Tidal C) in different
conditions that cause breathlessness. We will study whether the tidal breath carbon dioxide (TBCO2) waveform, as measured by
the N-Tidal C, has different characteristics in a range of respiratory and cardiac conditions.
Methods: We will perform a longitudinal, observational study of the TBCO2 waveform (capnogram) as measured by the N-Tidal
C capnometer. Participants with a confirmed diagnosis of asthma, breathing pattern disorders, chronic heart failure, motor neurone
disease, pneumonia, as well as volunteers with no history of lung disease will be asked to provide twice daily, 75-second TBCO2
collection via the N-Tidal C device for 6 months duration. The collated capnograms will be correlated with the underlying diagnosis
and disease state (stable or exacerbation) to determine if there are different TBCO2 characteristics that can distinguish different
respiratory and cardiac causes of breathlessness.
Results: This study’s recruitment is ongoing. It is anticipated that the results will be available in late 2018.
Conclusions: The General Breathing Record Study will provide an evaluation of the use of capnography as a diagnostic and
home-monitoring tool for various diseases.
Registered Report Identifier: RR1-10.2196/9767
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Introduction
Burden of Breathlessness
Respiratory and cardiac diseases that cause breathlessness are
both highly prevalent and major causes of health care utilization
across the United Kingdom. Asthma is estimated to affect over
3.5 million people, with 250,000 experiencing severe disease
with frequent exacerbations [1]. Heart failure (HF) affects over
half a million people, while every year up to 1% of the adult
population will suffer from a community-acquired pneumonia
[2,3]. Many of these patient groups experience comorbid
breathlessness such as breathing pattern disorders (BPD) [4].
The combined burden of these breathless patients on the
National Health Service (NHS) is enormous, accounting directly
for over £2 billion, with an indirect societal cost (time off work
and lost productivity) in excess of £6 billion [5-7]. The
prevalence of these diseases is increasing [8,9], and it is often
becoming difficult for the clinician to diagnose the cause of a
person’s breathlessness and, once diagnosed, considerably
difficult for the person to monitor their own disease effectively
[10]. Furthermore, patients who are at risk of hypercapnic failure
(eg, progressive motor neurone disease, MND) often find it
difficult to identify when their condition is deteriorating and
when they require more intensive support. The need for
noninvasive ventilation in these patients is often only recognized
when they are very ill and leads to an increased length of stay
in hospital and poorer patient outcomes [11].
Diagnostic Challenge
Current methods of diagnosing the cause of a person’s
breathlessness rely on a combination of symptom history and
extensive investigations such as spirometry, peak expiratory
flow rates, transthoracic echocardiography, blood tests, and
radiology. These can be invasive or are effort or technique
dependent, making them difficult to perform and often hard to
interpret. Many of these conditions lack a personal monitor that
can be used by patients at home, making it hard for patients to
self-monitor and engage with their management, resulting in
poor medicine adherence [12]. There is a need for a simple,
effort-independent tool that can aid the clinician in determining
a diagnosis and aid the patient in monitoring their condition. A
prompt diagnosis allows timely treatment, and accurately
identifying when action needs to be taken empowers the patient
and ultimately could improve outcomes.
Capnography
Capnometers graphically measure carbon dioxide (CO2) in
exhaled breath and provide clinicians with a noninvasive
measure of systemic metabolism, circulation, and ventilation.
Capnometers have been a standard of care in general anesthesia
for over 30 years and are also widely used in critically unwell
patients [13]. Their use is now even recommended to assess
adequate cardiopulmonary resuscitation in hospital cardiac
arrests [14,15]. However, use is currently limited to these
specialist hospital areas in part because of the high cost of
capnometers and the requirement for integrated information
systems by which data are displayed.
The Cambridge Respiratory Innovations Limited
“N-Tidal C” Capnometer
Cambridge Respiratory Innovations Limited (CRiL), a UK-based
company, has developed a novel infrared III-V light-emitting
diode capnometer that is intended for use by patients at home
to monitor their breathing condition. The N-Tidal C data
collector device is a class 1, Conformité Européene marked,
handheld device that measures the amount of CO2 in the user’s
breath during normal tidal breathing.
The device consists of the main unit and a disposable
mouthpiece. The device takes approximately 2 min to
self-calibrate. The patient then breathes normally through the
mouthpiece until the device gives an auditory and visual signal
that the reading is complete (75 seconds). The device records
the full dataset of exhaled CO2 for the duration of use, and the
data can be downloaded periodically. Data are analyzed using
algorithms developed by CRiL to produce waveforms and can
be viewed graphically. It has already been successfully used in
a longitudinal clinical study with 30 chronic obstructive
pulmonary disease (COPD) patients. This has resulted in the
collection of over 2600 75-second breath records containing
over 50,000 individual TBCO2 waveforms. This research
demonstrated a clear differentiation in TBCO2 waveforms
between stable COPD and during a COPD exacerbation [16].
It has also identified the early changes to TBCO2 waveform,
indicating an ability to predict COPD exacerbations [16].
We aim to establish a substantial TBCO2 waveform database
in multiple different conditions that cause breathlessness. This
study will determine whether this form of capnography can be
used as a tool for diagnosis of various respiratory and cardiac
conditions by comparing waveforms in different medical
conditions with healthy controls. It will also provide longitudinal
information in specific patient groups with chronic disease. This
will identify whether this use of capnography, as recorded by
the N-tidal C device, can be used as a self-monitoring tool by
patients at home.
Aims and Objectives
Coprimary Objectives
The coprimary objectives of this study are to explore the
characteristics of the TBCO2 waveform, as recorded by the
N-tidal C device, which can differentiate between different
respiratory and cardiac conditions, and to establish a TBCO2
profile for healthy controls.
Secondary Objectives
The secondary objectives for this study are as follows:
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• To identify within-patient changes in the TBCO2 waveform
that may predict or detect a deterioration of the underlying
disease.
• To establish whether the characteristics of any waveform
changes before a clinical deterioration are similar in all
patients in the same group.
• To identify waveform features that may help inform a larger
disease-specific prospective study in the future.
• To describe the relationship between characteristics of the
TBCO2 waveform and severity of the primary condition of
interest (as measured by disease-specific clinical parameters
and symptom questionnaires).
• To compare the use of the TBCO2 waveform (and the
N-Tidal C device) in monitoring different breathing
conditions with traditional methods of monitoring disease
control.
• To monitor the safety of the device in regular use by
participants over a 6-month period.
• To establish the ease of use of capnography measurement
as a potential method of disease diagnosis and monitoring
in all participants.
• To identify the ranges of TBCO2 waveform parameter
values (minimum and maximum) for the different disease
cohorts.
Methods
Overview
A longitudinal, observational study of several cohorts of patients
with different medical conditions that result in breathlessness.
Outcome Measures
Primary Outcome
For all conditions, the primary outcome of interest is the twice
daily TBCO2 waveform as recorded by the N-Tidal C device.
Safety Outcomes
Any adverse events (AEs) reported during performing the study
procedures and any adverse device effects will be recorded.
Patient or Health Care Professional Experience
Outcomes
A visual analog scale questionnaire to record the ease of use
and acceptability of the N-Tidal C device to participants and
health care professionals will be used at the completion of the
study.
Study Participants
Participants will be drawn from a range of clinical conditions
affecting adults that have symptoms of breathlessness.
Eligibility Criteria
There are overarching eligibility criteria for all clinical
populations, in addition to specific eligibility criteria, detailed
below for each clinical population, to ensure that the condition
of interest is clearly defined and that the participants will be
able to complete the study. These are shown in Textboxes 1 and
2.
Additional condition-specific inclusion criteria (definition of
required medical condition) are detailed below.
Asthma
Inclusion Criteria
The inclusion criteria was as follows:
1. A confirmed clinical diagnosis of asthma for ≥ 6months
supported by evidence of any of the following:
a. Airflow variability, with a variability in forced
expiratory volume in one second (FEV1) of >20%, with
concomitant evidence of airflow obstruction (FEV1/
forced vital capacity ratio <70% on spirometry)
recorded at any time;
b. Airway reversibility with an improvement in FEV1 by
≥12% or 200 ml after inhalation of 400 μg of
salbutamol via a metered dose inhaler and spacer within
the preceding 12 months;
c. Airway hyperresponsiveness demonstrated by
Methacholine (or similar) challenge testing with a
provocative concentration of Methacholine required to
cause a 20% reduction in FEV1(PC20) of ≤8 mg/ml or
equivalent test.
2. Moderate to severe asthma defined as British Thoracic
Society stage 3 to 5
3. Exacerbation free for >2 weeks (defined as no increased
dose or course of oral corticosteroids or antibiotics)
4. Two or more exacerbations in the previous 12 months with
at least one exacerbation within the last 6 months.
Textbox 1. Overarching inclusion criteria.
• Male or female, aged ≥16 years
• Willing and able to provide written informed consent
Textbox 2. Overarching exclusion criteria.
• Known other lung, chest wall, neuromuscular, cardiac, or other comorbidity or abnormality that would affect spirometry or other measures of
lung function or tidal breath carbon dioxide (TBCO2) measurements
• In the opinion of the clinical investigator, the participant would have difficulty completing the study procedures consistently over the course of
6 months
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Breathing Pattern Disorders
Inclusion Criteria
Each participant recruited must have a clinical diagnosis of a
BPD by a specialist respiratory physiotherapist.
Chronic Heart Failure
Inclusion Criteria
Each participant recruited must meet the following inclusion
criteria:
1. A confirmed clinical diagnosis of chronic HF with both of
the following:
a. A left ventricular ejection fraction <40% on most recent
imaging within the last 12 months.
b. New York Heart Association class 2 to 4
2. Either (i) admitted with an acute decompensation of their
HF to hospital requiring intravenous diuretics or an increase
in diuretic dose from baseline (eg, 40 mg or more
furosemide) within the last 6 months or (ii) stable outpatient
with N-terminal pro b-type natriuretic peptide (NT-proBNP)
>400 ng/mL in sinus rhythm or NT-proBNP >1000 ng/mL
in atrial fibrillation.
Motor Neurone Disease
Inclusion Criteria
Each participant recruited must have a confirmed clinical
diagnosis of motor neurone disease.
Pneumonia
Inclusion Criteria
Each participant recruited must have a confirmed clinical
diagnosis of pneumonia supported by evidence of consolidation
on a chest X-ray or computed tomography imaging.
Healthy Volunteers
Inclusion Criteria
The inclusion criteria was as follows:
1. No known history of lung, cardiac, or neuromuscular disease
(defined as no current clinical diagnosis of, or be receiving
treatment for, a lung, cardiac, or neuromuscular disease)
2. Body mass index ≤40
3. Nonsmoker, or ex-smoker with ≤ 5 pack year history
Sampling and Sample Size
As this is an observational, proof-of-concept study, there is no
formal statistical justification of the sample size, as the purpose
of this planned investigation is to gather data on TBCO2
waveform using the N-Tidal C device. If 70 participants use the
device 2 times daily over a period of 6 months, the database
should include up to 25,000 detailed 75-second respiration
records, which will allow time series analysis, comparisons,
and correlation with other measures of disease monitoring. This
study has been funded by a competitive grant awarded by
Innovate UK, and the number of participants recruited into each
patient cohort has been restricted by the number of available
devices built by CRiL based on the amount of grant funding.
Study Procedures
Recruitment
This study will be conducted at Queen Alexandra Hospital,
Portsmouth. Identification of potential participants will be
performed in outpatient clinics, inpatient wards, and specialist
secondary care clinics in the community depending on the
disease cohort. Furthermore, potential participants will also be
invited to attend patient information events about the study.
These events will be held over 2 hours and introduce the study
to potential asthma, BPD, and HF participants identified from
clinic lists. At these events, all participants will be given a
Participant Information Sheet (PIS), be introduced to the device,
and allowed to ask any questions. If interested in the study, they
will be given an appointment with the study team for a mutually
convenient screening visit. Participants will also be identified
at respiratory outpatient clinics and specialist respiratory clinics
in the community. In these settings, they will be given PIS and
an introduction to the study (verbal and written letter). Potential
HF and pneumonia participants will be identified from inpatient
wards and outpatient HF services, approached, and given a
verbal and written introduction to the study, along with a PIS
by a member of the research team. Healthy volunteers will be
recruited from hospital staff, with an email sent to all staff
(through the research communications team) advertising the
study. Potential volunteers will be asked to call or email the
study team so that further information (PIS) can be sent via
email and an appointment arranged to discuss the study further.
Screening and Enrollment
Patients who express an interest and give informed consent will
be screened for the study at an assessment visit at a convenient
date and time. Participants identified at the patient information
events will be given an appointment with the study team at the
event. Participants who are inpatients will undertake their first
assessment after they have provided informed consent—as an
inpatient and before discharge from hospital. Healthy volunteers
will be invited to an initial assessment visit at a mutually
convenient time.
Study Assessments
Schedule
The N-Tidal C capnometer will be explained to the patients,
and they will be trained how to use it. Patients will be asked to
use the device at home over a period of 6 months for the asthma,
BPD, HF, MND, and healthy control cohorts and a period of 2
months for the pneumonia cohort. Participants will be asked to
use the device at home 2 times per day (morning and evening),
or up to 6 times per day if they feel that they are starting an
exacerbation or deterioration of their condition. Hospitalized
inpatients will also use the device 2 times per day as inpatients
and will then continue with the monitoring after discharge from
hospital. All patients will have a clinical examination and
medical history recorded appropriate to their condition.
Additional disease-specific data such as lung or cardiac function
tests will be collected at baseline, 2, 4, and 6 months and at
point of exacerbation, depending on the underlying condition.
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The outline of assessments at each visit is detailed in Multimedia
Appendix 1
Home monitoring will commence as soon as the screening
assessments are complete for patients who are recruited from
outpatient clinics or specialist secondary clinics in the
community. They will commence the day after discharge from
hospital for patients who are recruited as inpatients. Home
monitoring will include daily N-Tidal C use and three weekly
symptom reporting:
1. N-Tidal C: patients will use the N-Tidal C, 2 times daily
(morning and evening), and up to 6 times daily if the patient
feels unwell or has a deterioration of their disease
throughout the home monitoring period until the final
outpatient clinic visit.
2. Symptom reporting: asthma, HF, BPD, and healthy
volunteer participants will have their disease specific
symptoms recorded 3 times a week via an automated
telephone service provided by a company called “Message
Dynamics.” This service has already been used and accepted
by patients in previous trials and uses participants’ responses
to preset questions to evaluate their state of health [17]. The
participants will record their symptoms by responding to a
series of questions using the telephone keypad. Using the
responses recorded, Message Dynamics will automatically
alert the study team if a participant’s state of health has
deteriorated beyond a given threshold. This will prompt a
telephone call from a member of the study team to the
participant to assess their condition and, if needed, arrange
a clinical review to diagnose an exacerbation. If the
participant does not answer the initial automated telephone
call, there will be no more than two follow-up calls (a
maximum of three in total).
At each study assessment, the use of the N-Tidal C device will
be reviewed. The study nurse will check that the patient is using
the device correctly and will provide additional training if
needed. The TBCO2 waveform data will be downloaded from
the device, and the study nurse will confirm that the mouthpieces
have been appropriately replaced at the required time intervals
Any AEs and any adverse device effects will be recorded. If
the patient feels that their condition is deteriorating and or they
are experiencing an exacerbation at any point throughout the
study, they will contact the study team, and, if appropriate, make
an appointment to be assessed as soon as mutually convenient.
The diagnosis of an exacerbation will be made by the assessing
clinician and appropriate treatment started. If the patient has
been diagnosed as having an exacerbation of their disease by a
different health care professional (eg, general practitioner, GP,
or practice nurse), they will be advised to contact the study team
as soon as possible to arrange an exacerbation assessment.
The Study Device: The N-Tidal C Capnometer
Description
The N-Tidal C data collector device is a novel infrared data
collector capnometer that is intended for use by patients at home.
It is a handheld device that measures the amount of CO2 in the
user’s breath during normal tidal breathing. It is simple to use;
instructions for the patient are provided. The device set consists
of the following:
• N-Tidal C Device x 1
• Mouthpieces x 6
• AA Batteries x 12
• Instructions for use (Participant’s) x 1
• Quick start guide (Participants’) x 1
• Storage case x 1
The mouthpieces should be changed each month.
The purpose of the device is to detect changes in the patient’s
exhaled CO2 waveform. However, the purpose of this planned
investigation is only to gather data on TBCO2 waveforms using
the N-Tidal C in different medical conditions and healthy
volunteers; the device will not be used to inform actions or
treatment for the patients.
CRiL is registered as a manufacturer of class 1 medical devices
with the Medicines and Healthcare products Regulatory Agency.
The N-Tidal C data-collector capnometer is the first of these,
and a batch of 70 devices have been built to medical device
Good Manufacturing Practices to meet the requirements of EN
ISO 13485. All of the devices have been tested individually
against set performance criteria as required for EN DIN
60601-90:1990, EN 21647:2004. All parts of the device that
have contact with the skin, mouth, or lips have been constructed
from medical grade plastic to mitigate biocompatibility risks.
Supply, Packaging, and Storage
The company has manufactured a batch of 70 N-Tidal C data
collector capnometers, and each device will be allocated a
unique serial number, allowing full tracking and traceability.
The device history record will reference details of all major
components and materials used in its manufacture. CRiL will
supply sufficient N-Tidal C devices to the investigative site for
each participant to have use of a single device. CRiL will also
supply the replacement mouthpieces to the site for use by the
study participants. Each participant will be supplied with six
mouthpieces. The study site will be supplied with additional
devices and mouthpieces for staff training and demonstration
and as additional stock. The N-Tidal C devices and mouthpieces
should be stored in a secure location at room temperature
(10°C-30°C).
Administration
CRiL will provide appropriate training to study staff on the use
of the N-Tidal C capnometer before the study commences.
Additional support will be made available should it be required.
In turn, the study staff will train the patients in the use of the
device and will provide further training if needed. The N-Tidal C
is for use in this study only and is not to be used for any other
purpose. The investigator or designee will maintain a full record
of device accountability. A device accountability log will be
maintained detailing the dispensing and return of the study
devices and mouthpieces. Used mouthpieces will be returned
at the end of the study for inspection for contamination and
degradation of performance; suitable containers will be provided
to participants for the return of these items.
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Device Use
The test will be performed as per the CRiL instructions.
Participants will use the N Tidal C data collector device twice
daily (morning and evening) and up to 6 times per day if the
patient feels their condition is deteriorating or they are having
an exacerbation. The capnometer recordings will be stored in
the device until they are downloaded periodically throughout
the study by the study staff. Participants will hold the device
and breathe at their normal, relaxed rate of breathing into a
disposable mouthpiece for 75 seconds. They will be asked to
do this twice a day for the study period (until 6 months for all
participants apart from those with pneumonia, who will cease
follow-up at 2 months). The mouthpiece should be changed
each month. It should not be used in crowded rooms, near a
vehicle exhaust, open flames, cigarettes, immediately after
drinking a hot beverage or a fizzy drink, or where there is a
strong breeze. These conditions may interfere with the data
capture of the device.
Disease Questionnaires
These will be completed only by the relevant cohort.
Asthma Control Questionnaire
The Asthma Control Questionnaire is a validated 7-item
questionnaire for assessing the level of asthma control over the
preceding 7 days. The questionnaire includes five symptom
scores, the frequency of rescue bronchodilator use, and a
measure of airway caliber (FEV1% predicted). Responses are
given on a 6-point scale, and the overall score is the mean of
the responses (0=totally controlled, 6=severely uncontrolled).
Scores over 1.0 are considered indicative of poor control [18].
Asthma Quality of Life Questionnaire
The Asthma Quality of Life Questionnaire is a validated 32-item
questionnaire that measures the functional problems (physical,
emotional, social, and occupational) that are most troublesome
to adults with asthma. Patients are asked to think about how
they have been over the previous 2 weeks and respond to each
of the 32 questions on a 7-point scale (7=not impaired at all,
1=severely impaired). The overall score is the mean of all 32
responses [19,20].
Nijmegen Questionnaire (Breathing Pattern Disorder
or Vocal Cord Dysfunction Cohort)
The Nijmegen score is derived from a 16-item questionnaire
that collects information on symptoms related to
hyperventilation, such as shortness of breath, feeling confused,
palpitations, and tingling fingers. Answers are based on a 5-point
Likert scale describing frequency of symptoms from “never”
to “very often.” A score of over 23 out of 64 suggests a possible
diagnosis of hyperventilation syndrome, and the questionnaire
can be used to assess the severity of the patient’s symptoms
during clinical assessments [21].
Dyspnoea-12 Questionnaire (Breathing Pattern Disorder
or Vocal Cord Dysfunction Cohort)
The Dyspnoea-12 Questionnaire is a 12-item questionnaire that
covers different aspects of breathing—eg, “my breath does not
go in all the way,” “my breathing makes me feel miserable,”
and “I feel short of breath.” The patient is asked to tick the box
that best reflects their breathing “these days” on a 4 point Likert
scale (none, mild, moderate, and severe) [22].
Vocal Cord Dysfunction Questionnaire
The Vocal Cord Dysfunction Questionnaire is a 12-item
questionnaire that has been validated in breathless patients with
the condition and can differentiate vocal cord dysfunction from
asthma. It rates the impact of 12 symptoms on a 5-point Likert
scale (total score range: 12-60). It has also been shown to assess
response to treatment [23].
Pittsburgh Vocal Cord Dysfunction Index Score
The Pittsburgh vocal cord dysfunction Index is a validated, easy
to use clinical tool that assigns patients a weighted score based
on symptoms of throat tightness (score of 4) and dysphonia
(score of 2), the absence of wheezing (score of 2), and the
presence of odors as a trigger for symptoms (score of 3). A
cutoff of ≥4 has high sensitivity and specificity for the diagnosis
of vocal cord dysfunction [24].
Kansas City Cardiomyopathy Questionnaire (Heart
Failure Cohort)
The Kansas City Cardiomyopathy Questionnaire is a 23-item,
self-administered instrument that quantifies physical function,
symptoms (frequency, severity, and recent change), social
function, self-efficacy and knowledge, and quality of life (QoL).
An overall summary score can be derived from the physical
function, symptom (frequency and severity), social function,
and QoL domains. For each domain, the validity, reproducibility,
responsiveness, and interpretability have been independently
established. Scores are transformed to a range of 0 to 100, in
which higher scores reflect better health status [25].
Curb-65
The CURB-65 is a clinical prediction rule that has been validated
for predicting mortality in community-acquired pneumonia.
The score is an acronym for each of the risk factors measured.
Each risk factor scores one point, for a maximum score of 5:
• Confusion of new onset (defined as an AMTS of 8 or less)
• Blood urea nitrogen greater than 7 mmol/l
• Respiratory rate of 30 breaths per minute or greater
• Blood pressure less than 90 mm Hg systolic or diastolic
blood pressure 60 mmHg or less
• Age 65 years or older
A higher score indicates greater severity of disease and a higher
risk of mortality [3].
Epworth Sleepiness Scale (Motor Neurone Disease
Cohort)
The Epworth Sleepiness Scale (ESS) is a self-administered
questionnaire with eight questions. Respondents are asked to
rate, on a 4-point scale (0-3), their usual chances of dozing off
or falling asleep while engaged in eight different activities. The
ESS score (the sum of 8 item scores, 0-3) can range from 0 to
24. The higher the ESS score, the higher that person’s average
sleep propensity in daily life [26].
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Description of Respiratory Tests
Fractional Nitric Oxide
Fractional exhaled nitric oxide will be measured using a NIOX
MINO device (Aerocrine AB, Solna, Sweden) or equivalent
device for measuring exhaled nitric oxide level, as specified by
the manufacturer’s instructions and outlined in the American
Thoracic Society and European Respiratory Society (ATS and
ERS) standards [27]. This includes collection by controlled
exhalation at the recommended controlled expiratory flow rate
of 50 ml/s for greater than 6 seconds.
Spirometry
Spirometry will be conducted using a spirometer conforming
to ATS and ERS standards as specified by the manufacturer’s
instructions [28]. Participants will inhale rapidly and completely
from functional residual capacity, then will exhale in an initial
blast of exhalation, and then continued exhalation until the end
of the test. FEV1(L), FVC (L), FEV1/ FVC ratio, FEF25-75(% of
predicted value), and peak expiratory flow (PEF; L/min) will
be recorded. FEV1, FVC, and PEF will be documented as both
absolute values and as a percentage of the predicted value.
Full Body Plethysmography
Full body plethysmography will be performed conforming to
ATS and ERS standards to assess static and dynamic lung
volumes and airways resistance [29]. The functional residual
capacity, residual volume, transfer factor (transfer factor for
carbon monoxide), and transfer coefficient (carbon monoxide
transfer coefficient) will be recorded as absolute values and as
a percentage of the predicted value.
Arterial Blood Gas
Arterial blood gases (pH, FiO2, pO2, pCO2, BE, HCO3, SaO2,
and SPO2) will be measured and recorded at every assessment
visit for the MND cohort. If any additional assessments are
taken as part of routine care while the patient is hospitalized or
in the community, the details will be recorded on the case report
form (CRF). For patients who are in hospital, arterial blood gas
measurements will be performed using the hospital’s standard
equipment.
Chest X-Ray
A diagnosis of pneumonia will be made by either a respiratory
physician or a radiologist on confirmation of consolidation on
a chest X-ray for the pneumonia group. The location of the
pneumonia will be recorded on the CRF.
Noninvasive Ventilator and Cough Assist Data
Only participants in the MND cohort who are established on
home noninvasive ventilation will have their home ventilator
data recorded on the CRF at their routine 3-monthly clinic
appointment. This will include inspiratory positive airways
pressure, expiratory positive airways pressure, average tidal
volumes, hours of use of noninvasive ventilation, mask leak,
and type of interface used (nasal or full face mask). These data
will be taken off the ventilator and, if applicable, cough assist
machine, and therefore will not include any additional testing
for participants.
Description of Cardiac Function Tests
Transthoracic 2D Echocardiography
An echocardiogram is a test that uses ultrasound waves to
measure the function and structure of the heart, including the
heart valves and pressures within different chambers. It is part
of routine care for patients admitted with an acute
decompensation of their HF [30]. A comprehensive echo will
be performed in accordance with the British Society of
Echocardiography guidelines [31].
N-Terminal Pro-B-Type Natriuretic Peptide
The NT pro-BNP blood test will be performed on all patients
in the HF cohort. This is a validated diagnostic and prognostic
test for people presenting with HF and its assessment is part of
the National Institute of Clinical Excellence guidelines [30].
New York Heart Association Class
The New York Heart Association classification is a routinely
used functional assessment to classify the severity of HF purely
based on assessment of impact of symptoms on daily activities.
It places patients into one of four categories from class 1 (no
limitation of physical activity) to class 4 (symptoms of HF at
rest) [32]
Other Clinical Tests
Full Blood Count and Peripheral Blood Eosinophil
Count
The full blood count will be taken and recorded in the asthma,
HF, and pneumonia groups. In hospital, if further blood samples
for routine hematological and biochemistry are taken, then these
will be recorded in the CRF.
Skin Prick Testing
Asthma participants will have a skin prick test (SPT) performed
to determine their atopic status. If the participant has had a SPT
performed and recorded within the last 3 years, then this result
will be used. A SPT is a simple and safe method of testing a
person to determine whether or not they have an IgE-mediated
allergic response to common inhaled allergens. SPT’s will be
performed by trained and experienced respiratory health care
professionals, who are also trained in resuscitation techniques.
Five common aero-allergens will be tested for: grass, house
dust mite, aspergillus, and cat and dog dander. Atopic status
will be demonstrated by a positive SPT (wheal diameter ≥3 mm
larger than the negative control) [33].
Symptom Questionnaires (To Be Reported Three
Times a Week via the Automated “Message Dynamics”
System)
Asthma Cohort Symptoms
Asthma patients will report their symptoms 3 times a week
(Monday, Wednesday, and Friday) via the automated telephone
system provided by Message Dynamics. Each participant will
be telephoned at a predetermined, agreed time of day. If the
participant does not answer the initial telephone call, they will
receive no more than two follow-up calls (maximum three in
total). The presence or absence of four asthma symptoms during
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a 24-hour period will be recorded (scoring 0 for absence of
symptoms or 1 for presence of symptoms) alongside the number
of times asthma reliever medication is used. This will provide
a symptom score (from 0-4) and combined with the frequency
of reliever medication used, a composite score (from 0-6, Table
1). Questions asked on the automated telephone system will be
as follows:
1. Have you experienced regular wheeze in the last 24 hours?
(yes or no)
2. Have you been woken at night by your asthma in the last
24 hours? (yes or no)
3. Has your asthma caused chest tightness in the last 24 hours?
(yes or no)
4. Have you been more breathless than normal over the last
24 hours? (yes or no)
5. How many times have you used your salbutamol (ventolin)
inhaler in the last 24 hours? (option 1: ≤2, option 2: 3-9,
and option 3: ≥10).
A score ≥4 would alert the study team and prompt a member
of the study team to call the participant.
Healthy Volunteer Cohort Respiratory Symptoms
The healthy cohort will be asked to record upper and lower
respiratory tract symptoms 3 times a week via the automated
telephone system provided by Message Dynamics. Each
participant will be telephoned at a predetermined, agreed time
of day. If the participant does not answer the initial telephone
call, they will receive no more than two follow-up calls
(maximum three in total). The presence or absence of three
symptoms during a 24-hour period will be recorded (scoring 0
for absence of symptoms or 1 for presence of symptoms). This
will provide a symptom score (range 0-3, Table 2). Questions
asked on the automated telephone system will be as follows:
1. Have you had a runny or blocked nose in the last 24 hours?
(yes or no)
2. Have you had any sinus pain in the last 24 hours? (yes or
no)
3. Have you had a cough in the last 24 hours? (yes or no)
Breathing Pattern Disorders Cohort Symptoms
The BPD cohort will be asked to record presence of symptoms
3 times a week via the automated telephone system provided
by Message Dynamics. Each participant will be telephoned at
a predetermined, agreed time of day. If the participant does not
answer the initial telephone call, they will receive no more than
two follow-up calls (maximum three in total). The presence or
absence of three symptoms during the previous 24-hour period
will be recorded (scoring 0 for absence of symptoms, or 1 for
presence of symptoms). This will provide a daily symptom score
(range 0-3, Table 3). Questions asked on the automated
telephone system will be as follows:
1. Have you had breathlessness in the last 24 hours? (yes or
no)
2. Have you had chest tightness in the last 24 hours (yes or
no)
3. Does your breathing feel tense in the last 24 hours? (yes or
no)
Table 1. Symptoms present in the last 24 hours, reliever use, and assigned score.
ScoreParameter
1Wheeze
1Night waking
1Chest tightness
1Breathlessness
4Maximum symptom score
Reliever use
0≤2
13-9
2≥10
6Maximum composite score total
Table 2. Upper respiratory and chest symptoms present in the last 24 hours and assigned score.
ScoreParameter
1Runny or blocked nose
1Sinus pain
1Cough
3Maximum score
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Table 3. Symptoms present in the last 24 hours and assigned score.
ScoreParameter
1Breathlessness
1Chest tightness
1Feeling tense
3Maximum score
Table 4. Symptoms present in the last 24 hours and assigned score.
ScoreParameter
1Breathlessness
1Chest tightness
1Fatigue
1Leg swelling
4Maximum score
Chronic Heart Failure Cohort Symptoms
The HF cohort will be asked to record symptoms 3 times a week
via the automated telephone system provided by Message
Dynamics. Each participant will be telephoned at a
predetermined, agreed time of day. If the participant does not
answer the initial telephone call, they will receive no more than
two follow-up calls (maximum three in total). The presence or
absence of four symptoms during the previous 24-hour period
will be recorded (scoring 0 for absence of symptoms or 1 for
presence of symptoms). This will provide a daily symptom score
(range 0-4, Table 4). Questions asked on the automated
telephone system will be as follows:
1. Have you had breathlessness in the last 24 hours? (yes or
no)
2. Have you had chest tightness in the last 24 hours (yes or
no)
3. Have you felt more tired than normal in the last 24 hours?
(yes or no)
4. Have your legs swelled up more than normal in the last 24
hours? (yes or no)
A score ≥4 would alert the study team and prompt a member
of the study team to call the participant.
Ease of Use Questionnaire for Participants
A brief self-completed visual analog scale questionnaire will
be used to evaluate participants’ opinions of the N-Tidal C
device at the end of the study.
Test Acceptability Questionnaire for Staff
At the end of the study, a questionnaire will be used to evaluate
health care professionals’ opinions of the different study
assessments. Informed consent will be obtained from each health
care professional to participate within the study. Only health
care professionals who taught and assessed the N-Tidal C device
during the study to a minimum of 5 patients will be asked to
participate.
Safety Assessment
Definitions
Adverse Event
An AE is any untoward medical occurrence in a participant
taking part in a clinical trial that does not necessarily have to
have a causal relationship with the device under investigation.
An AE can therefore be any unfavorable or unintended sign,
symptom, or disease temporarily associated with the use of the
device, whether or not this has a causal relationship with the
device under investigation.
Adverse Device Event
Adverse device effects are all untoward and unintended medical
occurrences in response to a medical device. All cases judged
by either a medically qualified professional or the sponsor as
having a reasonable suspected causal relationship to the device
qualify as a device effect. This also includes any event resulting
from insufficiencies or inadequacies in the instruction for use
or deployment of the device and includes any event that is a
result of a user error.
Serious Adverse Events
A serious adverse event is any untoward medical occurrence
that
• Results in death
• Is life-threatening. The term “life-threatening” in the
definition of “serious” refers to an event in which the
participant was at risk of death at the time of the event; it
does not refer to an event that hypothetically might have
caused death if it were more severe.
• Requires inpatient hospitalization or prolongation of existing
hospitalization
• Results in persistent or significant disability or incapacity
• Is a congenital anomaly or birth defect
• Results in other important medical events
Other events that may not result in death, are not life-threatening,
or do not require hospitalization may be considered a serious
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AE when, based upon appropriate medical judgment, the event
may jeopardize the participant and may require medical or
surgical intervention to prevent one of the outcomes listed above.
Serious Adverse Device Effect
A serious adverse device effect (SADE) in a participant taking
part in a clinical trial does not necessarily have to have a causal
relationship with the device under investigation. However, a
SADE is defined as any untoward medical occurrence seen in
a patient that can be attributed wholly or partly to the device,
which resulted in any of the characteristics or lead to the
characteristics of a SADE.
A SADE is also any event that may have led to these
consequences if suitable action had not been taken or an
intervention had not been made or if circumstances had been
less opportune. A SADE will be documented on a serious
adverse event form.
Planned admission to hospital for a preexisting condition will
not be considered an serious adverse event.
Recording and Reporting of Adverse Events
Participants will be asked about the occurrence of any AEs at
each follow-up visit and will be asked to report AEs to their
local study team between visits. AEs will be assessed by the
principal investigator (PI) for causality, intensity, seriousness,
and expectedness. Only AEs that have a reasonable possibility
of being attributable to the device and any other AE considered
to be of clinical significance by the PI as causing harm to the
patient will be recorded in the CRF and reported to the sponsor
as per their guidelines. Any AEs that do occur and are
considered by the PI to be related to the device will be expedited
to the sponsor, research ethics committee (REC), and the device
manufacturer within 7 days. Lists of the AEs will be provided
to the sponsor when requested.
Expected Adverse Events and Serious Adverse Events
Exempt From Recording
In the different cohorts under investigation, participants may
experience an expected deterioration in their condition and a
number of serious or nonserious events throughout the course
of the study. In the asthma group, participants may be expected
to experience:
• An increase in rescue medication usage
• Additional courses of steroids for asthma exacerbations
• Increased unscheduled healthcare usage, including GP and
emergency department (ED) visits for deteriorations in
asthma control
• Time off work, college, or university because of worsening
asthma control
• Hospitalization because of asthma exacerbation
In the HF group, participants may be expected to experience:
• Increase in their diuretic treatment
• Increased unscheduled healthcare usage, including GP and
ED visits for deteriorations in their HF symptoms
• Further hospitalizations for acute decompensation of their
heart failure.
In the MND group, participants may be expected to experience:
• An increase in medication use
• Additional courses of antibiotics for infections
• Increased unscheduled health care usage, including GP,
ED. and high care visits for deteriorations in their MND
• Hospitalization because of worsening respiratory failure
• Natural progression of their MND leading to death.
In the BPD group, participants may be expected to experience:
• Increased unscheduled health care usage, including GP and
ED visits for deteriorations in their symptoms
• An increase in any rescue medication use
Data Handling and Analysis
Data Collection and Management
Enrollment into the study will be documented in each
participant’s medical notes.
Data collection will comprise
• Paper CRF, including participant characteristics; disease
severity; medication lists; clinical examination; and
pulmonary, cardiac, radiological, and blood test results.
• Disease specific symptom, control, and QoL questionnaires.
• Paper self-completed questionnaire for participants.
• The N-Tidal C data collector recordings will be downloaded
directly from the device onto computers supplied by the
sponsor.
Data management will be conducted by CRiL. All data
management procedures will be completed in accordance with
CRiL Standard Operating Procedures. Before data being
received in-house, it will be monitored at the investigator site.
CRF and other data documentation removed from the
investigator site will be tracked by the monitor. When errors in
clinical data are discovered during data entry, a query will be
created. Queries are created when information is missing or is
illegible and needs further clarification. Query forms will be
sent to the investigator for completion.
Data Analysis
Primary Analysis
All participants with recorded TBCO2 waveforms will be
analyzed. Subgroup analysis will be performed on the different
study groups, namely, asthma, BPD, HF, MND, pneumonia,
and healthy controls.
Analysis of End Points
Summary Statistics
Demographics or baseline characteristics of each of the study
groups (asthma, BPD, HF, MND, pneumonia, and control) will
be produced separately, as well as summaries for all groups
combined. Normally, distributed continuous variables will be
summarized by the mean and SD, whereas the median and
interquartile range will be preferred for non-normally distributed
continuous variables.
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Primary Analysis
To establish our primary objective, CRiL will be using a variety
of advanced analytic techniques to isolate the key characteristics
in the capnogram that can identify each specific medical
condition under investigation and to determine whether there
is a difference between the different conditions. The team has
developed algorithms to analyze specifics of the TBCO2
waveform using modern computing technology. We will use
an expert in machine learning to analyze the large dataset this
study will produce. Specifically, we will analyze all components
of the TBCO2 waveform. The TBCO2 waveform is made up of
successive phases; phase 1 is a latency phase representing
baseline inspired gas from the ventilatory dead space. Phase 2
is a rapid upward curving slope representing expired mixed air
containing CO2. Phase 3 is a plateau phase representing the
partial pressure of CO2 exchanged at the alveoli. The alpha
angle (between phase 2 and phase 3 of the waveform), the peak
end tidal CO2 level, and the beta angle (between phase 3 and
the inspiratory downstroke) will all be recorded. Novel parts of
the waveform will also be analyzed as more information is found
about the TBCO2 waveform throughout the study. The analysis
will include looking at the consistency of a participants repetitive
breathing pattern, any changes between disease and healthy,
and any changes between disease state (stable vs exacerbation).
Secondary Analyses
Associations between the recorded capnogram and other disease
specific measures of severity, clinical condition (stable,
exacerbating), and disease control will be examined.
Procedure for Dealing With Missing and Spurious Data
The analysis will include any measured data values, with missing
values omitted from the analysis. No imputation of missing data
will be performed. The data will be examined for outlying
values. Where possible, these will be retained in the data analysis
and their influence minimized by a data transformation or a
nonparametric approach. If such approaches are not practical,
the analysis of the primary outcome will be performed twice,
with and without the outlying values.
Ethics
Participant Confidentiality
The study staff will ensure that the participants’ anonymity is
maintained. The participants will be identified only by initials
and a participant’s identity document number on the CRF and
any electronic database. All documents will be stored securely
and only accessible by study staff and authorized personnel.
The study will comply with the Data Protection Act that requires
data to be anonymized as soon as it is practicable to do so.
Other Ethical Considerations
The study gained approval form South Central—Berkshire NHS
Research Ethics Committee (REC reference 17/SC/0284) on
July 17, 2017. The ethics committee reviewed and approved
the protocol and all study relevant material such as the informed
consent forms and PISs. Any changes to protocol or relevant
study documents will be approved by the sponsor. Should an
amendment be made that requires REC approval, as defined by
REC as a substantial amendment, the changes will not be
instituted until the amendment has been reviewed and received
approval or favorable opinion from the REC and research and
development departments. A protocol amendment intended to
eliminate an apparent immediate hazard to participants may be
implemented immediately, providing that the REC are notified
as soon as possible and an approval is requested. Minor
amendments as defined by REC as nonsubstantial amendment
may be implemented immediately; and the REC will be
informed. All participants will have adequate time to consider
participation in the study, as per Good Clinical Practice
guidelines [34].
There is a possibility that the study procedures reveal potential
new, previously unknown disease pathology. This would be
more likely to occur in our healthy controls. If such a
circumstance occurs, then the participant will be told of the
results and immediately referred to the most appropriate NHS
department for further review. With the participant's consent,
a letter will be written to their GP explaining the findings.
Informed Consent
It is the responsibility of the investigator, or a person designated
by the investigator (if acceptable by local regulations), to obtain
written informed consent from each person participating in this
study, after adequate explanation of the aims, methods,
anticipated benefits, and potential hazards of the study using
the PIS. The consent process will be documented in the
participant’s notes.
The process for obtaining participant informed consent will be
in accordance with the REC guidance, and Good Clinical
Practice and any other regulatory requirements that might be
introduced. The PI or delegate and the participant or other
legally authorized representative shall both sign and date the
informed consent form before the person can participate in the
study. The participant will keep the PIS and a copy of the signed
and dated consent form. The original will be retained in the trial
master file. A second copy will be filed in the participant’s
medical notes and a signed and dated note made in the notes of
when the PIS was provided and that informed consent was
obtained for the study.
The decision regarding participation in the study is entirely
voluntary. The investigator or their nominee shall emphasize
to them that consent regarding study participation may be
withdrawn at any time without penalty or affecting the quality
or quantity of their future medical care, or loss of benefits to
which the participant is otherwise entitled.
Patient and Public Involvement
Patient and public involvement in this study has been obtained
from patients with firsthand experience of living with
breathing-related diseases. Initially, patients from our Wessex
Asthma Network identified the need for new tools (especially
for those with severe disease) to be developed and tested that
allows them to reliably monitor their asthma at home or at the
surgery or hospital, which does not involve forced breathing,
and can alert them when an exacerbation is about to occur. If it
could also detect whether someone has asthma or a different
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cause of their breathlessness, then that would help many more
people get an early diagnosis and treatment.
Working with patients in Wessex, we approached several
innovators and UK companies to challenge them to produce
new tools for people who suffer from conditions that affect their
breathing. CRiL is such a company which has developed a
unique tool (N-Tidal C) that could be used for exactly this
purpose. Working with our patient advisors, we have designed
a simple study with this new device that will compare
information from patients with different breathing conditions
to healthy people.
Our patient representatives have specifically contributed to the
study design, screening and recruitment strategies, shape of the
protocol, PIS, the lay summary, and the participant
self-completion questionnaire. They are also satisfied that this
study will not be excessively burdensome to participants.
Results
Recruitment to the General Breathing Record Study is ongoing.
It is anticipated that results will be available by late 2018.
Discussion
The General Breathing Record Study will provide evaluation
of a new handheld capnometer, the N-Tidal C. It will assess the
use of capnography in differentiating different respiratory and
cardiac diseases compared with healthy controls. It will provide
some data on the use of capnography as a tool to detect
deterioration in disease state. The study will also allow us to
develop the device further in response to participant feedback.
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Abbreviations
AE: adverse event
BPD: breathing pattern disorders
COPD: chronic obstructive pulmonary disease
CRF: case report form
CRiL: Cambridge Respiratory Innovations Limited
ED: emergency department
ESS: Epworth Sleepiness Scale
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
HF: heart failure
MND: motor neurone disease
NHS: National Health Service
NT-proBNP: N-terminal pro b-type natriuretic peptide 
PEF: peak expiratory flow rate
PI: principal investigator
PIS: Participant Information Sheet
QoL: quality of life
REC: research ethics committee
SADE: serious adverse device effect
SPT: skin prick test
TBCO2: tidal breathing carbon dioxide
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